Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Asthma Asthmatic symptoms during the last year and at least one criterion of the below: 1. current FEV1-increase of minimum 12% after b2-agonist, 2. positiv Methacholintest, 3. Day-to-day FEV1-variation of at least 20% during a two-week period. 4. Positive mannitol test. Furthermore, all of the below At least 10 packyears At least 10 cigarettes per day within the last year Age 18-40 years  Asthmatics who have been treated with inhaled corticosteroids (ICS), systemic corticosteroids, leukotrien-antagonists (LTA), long-lasting b2-agonists, anticholinergic medicine or varenicline within the last 3 months 2. Lower respiratory tract infections, including pneumonia, within the last 6 weeks. 3. Patients suffering from other chronic respiratory disease than asthma, such as sarcoidosis and COPD will also be excluded. 4. Pregnant and nursing women will be excluded as well as women planning pregnancy during the study period. 5. A history of allergy towards study drugs will lead to exclusion. Patients who during the study period develop lower respiratory infections or due to severe uncontrolled asthma receive treatment with any of the above listed types of medicine will be excluded. Patients who are diagnosed with other chronic respiratory disease than asthma during the study period will also be excluded, as well as patients who during the study period require more asthma medicine than the planned study medication. Any participant who wishes to leave the study, for any reason, including unacceptable side-effects, during the study period will be excluded, as well as anyone who wants to withdraw their recorded data from the project after the study period has ended. In case of unacceptable side-effects to varenicline resulting in immediate cessation of treatment with this drug, the participant will continue visits unchanged, but he/she will be excluded from the calculations of tobacco cessation succes-rate. However, varenicline cessation up to 4 weeks after treatment start with varenicline will result in and replacement of the participant. Cessation of treatment with budesonide will result in from the rest the study. The person will not be replaced. The data recorded from the participant until the last visit before cessation will be used. Allergic reactions towards study drugs will result in immediate cessation of the drug, and possible as described in the above. -